ArticleResearch square2026
Risk-Stratified versus Cytology-Based Triage of Non-HPV 16/18-Positive for Detection of High-Grade Cervical Intraepithelial Neoplasia: Protocol of a Non- Inferiority Randomized Controlled Trial.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background: Human papillomavirus (HPV)-based screening is increasingly being adopted as the primary strategy for cervical cancer prevention due to its superior sensitivity compared with cytology. However, effective triage of women who test positive for high-risk HPV (hrHPV), particularly those infected with non-HPV16/18 genotypes, remains a significant challenge in low-resource settings. Cytology-based triage requires substantial laboratory infrastructure and technical expertise, which may limit its scalability. Risk-stratified triage approaches incorporating readily available clinical and demographic factors may offer a practical alternative for identifying women at highest risk of cervical precancer while reducing unnecessary referrals. Aim: The " Methods: This protocol describes a two-arm, parallel, open-label, non-inferiority randomized controlled trial involving sexually active women aged 30-65 years who test positive for non-HPV16/18 high-risk HPV types during routine cervical cancer screening at the Lagos University Teaching Hospital (LUTH), Lagos, Nigeria, between June 2026 and January 2027. A total of 148 eligible women will be randomized in a 1:1 ratio to either a risk-stratified triage arm or a cytology-based triage arm. Participants in the intervention arm will be triaged using a composite algorithm incorporating age, HIV status, cigarette smoking, long-term oral contraceptive use, and multiple hrHPV genotype infections, while participants in the control arm will undergo reflex cytology according to the Bethesda 2014 classification. The primary outcome is the proportion of histologically confirmed CIN2 + lesions detected in each study arm. Secondary outcomes include diagnostic performance metrics, referral rates for colposcopy, colposcopic yield, and predictors of CIN2+. Analyses will follow the intention-to-treat principle. Differences in CIN2 + detection rates will be assessed using risk differences and corresponding 95% confidence intervals. Non-inferiority will be concluded if the lower bound of the confidence interval exceeds the pre-specified non-inferiority margin of - 10%. Logistic regression analyses will be used to identify independent predictors of CIN2+, and statistical significance will be set at P < 0.05. Discussion: The " Registration: : PACTR202606895128487 (2nd June 2026).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.